AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Ritholtz Wealth Management

Ritholtz Wealth Management boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZNGet Rating) by 11.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,156 shares of the company’s stock after acquiring an additional 2,945 shares during the quarter. Ritholtz Wealth Management’s holdings in AstraZeneca were worth $1,860,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. DB Wealth Management Group LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $26,000. Parkside Financial Bank & Trust lifted its position in shares of AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares in the last quarter. Baltimore Washington Financial Advisors Inc. purchased a new stake in AstraZeneca during the fourth quarter worth about $27,000. Fairfield Bush & CO. purchased a new position in AstraZeneca during the first quarter valued at approximately $28,000. Finally, Quent Capital LLC bought a new stake in AstraZeneca during the 4th quarter valued at $31,000. 21.55% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of AZN traded down $1.42 during trading hours on Friday, hitting $54.89. The company’s stock had a trading volume of 242,943 shares, compared to its average volume of 6,799,223. The company has a market cap of $170.10 billion, a price-to-earnings ratio of -133.83, a PEG ratio of 1.09 and a beta of 0.44. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.96 and a quick ratio of 0.67. AstraZeneca PLC has a 52-week low of $53.63 and a 52-week high of $71.70. The business has a 50 day simple moving average of $63.80 and a two-hundred day simple moving average of $64.70.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were given a dividend of $0.465 per share. The ex-dividend date was Thursday, August 11th. This represents a yield of 2.2%. AstraZeneca’s dividend payout ratio is presently -221.95%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Citigroup raised their target price on shares of AstraZeneca from £105 ($126.87) to £130 ($157.08) in a report on Tuesday, July 12th. UBS Group downgraded AstraZeneca from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 14th. Credit Suisse Group lowered AstraZeneca from an “outperform” rating to a “neutral” rating in a report on Thursday, September 15th. TheStreet cut shares of AstraZeneca from a “b-” rating to a “c” rating in a research note on Tuesday, August 30th. Finally, Morgan Stanley lowered shares of AstraZeneca from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, September 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8,840.50.

AstraZeneca Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Want to see what other hedge funds are holding AZN? Visit to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.